share_log

Genfleet Therapeutics Announced Clinical Trial Collaboration And Supply Agreement With BeiGene Switzerland To Start A Combination Study Of GFH009 And Brukinsa (Zanubrutinib) In Phase 1B/2 Trial For Diffuse Large B Cell Lymphoma

Genfleet Therapeutics Announced Clinical Trial Collaboration And Supply Agreement With BeiGene Switzerland To Start A Combination Study Of GFH009 And Brukinsa (Zanubrutinib) In Phase 1B/2 Trial For Diffuse Large B Cell Lymphoma

Genfleet Therapeutics 宣佈與瑞士百濟神州達成臨床試驗合作和供應協議，在瀰漫性大 B 細胞淋巴瘤的 1B/2 期試驗中啓動 GFH009 和布魯金薩（Zanubrutinib）的聯合研究
Benzinga ·  03/28 19:14

Genfleet Therapeutics Announced Clinical Trial Collaboration And Supply Agreement With BeiGene Switzerland To Start A Combination Study Of GFH009 And Brukinsa (Zanubrutinib) In Phase 1B/2 Trial For Diffuse Large B Cell Lymphoma

Genfleet Therapeutics 宣佈與瑞士百濟神州達成臨床試驗合作和供應協議，在瀰漫性大 B 細胞淋巴瘤的 1B/2 期試驗中啓動 GFH009 和布魯金薩（Zanubrutinib）的聯合研究

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論